MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its fourth quarter financial results for 2021 on February 24, 2022, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and corporate progress. Investors can access the call by dialing (877) 303-6253 domestically or (973) 409-9610 internationally, with a Conference ID of 1067087. A webcast will also be available on the company's website.
- None.
- None.
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2021 after the market closes on Thursday, February 24, 2022. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, February 24, 2022, at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 1067087.
The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
FAQ
When will MacroGenics release its financial results for Q4 2021?
What time is the conference call for MacroGenics' Q4 results?
How can I access the MacroGenics conference call?
Where can I find the webcast of the MacroGenics conference call?
